Letter

Antidepressant trials generally have methodological defects

BMJ 2001; 323 doi: 10.1136/bmj.323.7312.574 (Published 8 September 2001)
Cite this as: BMJ 2001;323:574.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Christian Even, praticien hospitalier (evenlafitte@compuserve.com),
  2. Serge Friedman, attaché de consultation,
  3. Roland Dardennes, praticien hospitalier
  1. Hôpital Sainte-Anne, Clinique des Maladies Mentales et de l'Encéphale (Service du Pr Guelfi), Université Paris V, 75674 Paris Cedex 14, France

    EDITOR—The study reported by Woelk tried to show the antidepressant properties of St John's wort,1 but its methodology was subsequently much criticised.2 We put the four major criticisms together to form a short “methodological quality” checklist and added one item regarding the integrity of blindness: the checklist assessed use of remission criteria; use of a three arm design; use of an active placebo; individual determination of the dose of the reference compound; and evaluation …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular